These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23676973)

  • 21. Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats.
    Ono M; Sawa Y; Fukushima N; Suhara H; Nakamura T; Yokoyama C; Tanabe T; Matsuda H
    Eur J Cardiothorac Surg; 2004 Dec; 26(6):1092-7. PubMed ID: 15541968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
    Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
    Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling.
    Uchida T; Hazekawa M; Yoshida M; Matsumoto K; Sakai Y
    J Pharmacol Sci; 2013; 123(4):392-401. PubMed ID: 24292413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats.
    Prié S; Leung TK; Cernacek P; Ryan JW; Dupuis J
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1312-8. PubMed ID: 9316840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
    Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
    J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels.
    Shen L; Shen J; Pu J; He B
    Cell Biochem Biophys; 2011 Sep; 61(1):23-31. PubMed ID: 21327581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.
    Cui B; Cheng YS; Dai DZ; Li N; Zhang TT; Dai Y
    Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):169-75. PubMed ID: 18986320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
    Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
    Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
    Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
    Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats.
    Ueno M; Miyauchi T; Sakai S; Goto K; Yamaguchi I
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S305-10. PubMed ID: 11078405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
    Tahara N; Kai H; Niiyama H; Mori T; Sugi Y; Takayama N; Yasukawa H; Numaguchi Y; Matsui H; Okumura K; Imaizumi T
    Hum Gene Ther; 2004 Dec; 15(12):1270-8. PubMed ID: 15684702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats.
    Ito T; Okada T; Mimuro J; Miyashita H; Uchibori R; Urabe M; Mizukami H; Kume A; Takahashi M; Ikeda U; Sakata Y; Shimada K; Ozawa K
    Hypertension; 2007 Sep; 50(3):531-6. PubMed ID: 17635855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced Pulmonary Vascular and Alveolar Development via Prenatal Administration of a Slow-Release Synthetic Prostacyclin Agonist in Rat Fetal Lung Hypoplasia.
    Umeda S; Miyagawa S; Fukushima S; Oda N; Saito A; Sakai Y; Sawa Y; Okuyama H
    PLoS One; 2016; 11(8):e0161334. PubMed ID: 27529478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.
    Zhao YD; Courtman DW; Deng Y; Kugathasan L; Zhang Q; Stewart DJ
    Circ Res; 2005 Mar; 96(4):442-50. PubMed ID: 15692087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats.
    Itoh T; Nagaya N; Fujii T; Iwase T; Nakanishi N; Hamada K; Kangawa K; Kimura H
    Am J Respir Crit Care Med; 2004 Jan; 169(1):34-8. PubMed ID: 14525801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transfer of human hepatocyte growth factor reduces inflammation and prevents pulmonary arterial remodeling in monocrotaline-induced.
    Chen J; Zhang H; Zhang R; Liu Z; Wang J; Xiao M; Ba M; Yao F; Liu J; Huang S; Zhong J
    Int J Clin Exp Pathol; 2014; 7(12):8763-9. PubMed ID: 25674243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
    Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension.
    Wang Y; Hu F; Mu X; Wu F; Yang D; Zheng G; Sun X; Gong K; Zhang Z
    Biorheology; 2016 Jan; 53(1):13-22. PubMed ID: 26889655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.